Alliance to Develop Cell-Based Assays

(Boston, MA, USA) and BioImage (Copenhagen, Denmark). The assays will be designed for the PerkinElmer EnVision HTS multilabel plate reader platform.

BioImage is a leader in using protein translocation-based technology to identify novel therapeutics. The collaboration combines the BioImage assay technology with PerkinElmer EnVision detection platform to develop a series of cell-based screening methods. BioImage has developed a suite of assay technologies for measuring protein-protein interactions in living cells using PerkinElmer's EnVision platform. The EnVision provides extremely sensitive fluorometric detection at high speeds, making it a good detection platform for the BioImage assays. This combination enables customers to perform robust cell-based identification of inhibitors of protein/protein interactions at throughput levels previously not available.

"This agreement provides a logical avenue for us to commercialize some of our technologies and collaborate with the leading provider of plate readers in the high- throughput screening market,” said Dr. Patrik Dahlen, CEO of BioImage. "We are actively out-licensing our IP [intellectual property] estate and marketing our assay development services, and are confident that the assays validated on the EnVision platform will be of great interest to many biopharmaceutical companies.”


Related Links:
PerkinElmer
BioImage